Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis
Authors
Keywords
Obeticholic acid, NASH, Cholestatic liver disease, PBC, PSC, Meta-analysis
Journal
Clinics and Research in Hepatology and Gastroenterology
Volume 45, Issue 3, Pages 101675
Publisher
Elsevier BV
Online
2021-03-19
DOI
10.1016/j.clinre.2021.101675
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis
- (2020) Rohit Loomba et al. HEPATOLOGY
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
- (2020) Kris V. Kowdley et al. JOURNAL OF HEPATOLOGY
- Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
- (2020) Albert Parés et al. LIVER INTERNATIONAL
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
- (2020) Francisco Idalsoaga et al. Frontiers in Medicine
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Obeticholic acid may increase the risk of gallstone formation in susceptible patients
- (2019) Samer Al-Dury et al. JOURNAL OF HEPATOLOGY
- Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
- (2019) Michael Trauner et al. Lancet Gastroenterology & Hepatology
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
- (2019) Slavica Lazarević et al. PHARMACOLOGICAL RESEARCH
- Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
- (2019) Christopher L. Bowlus et al. Clinical Gastroenterology and Hepatology
- Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid
- (2019) John E Eaton et al. HEPATOLOGY
- Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
- (2019) Mohammad Shadab Siddiqui et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
- (2019) Michael K. Badman et al. Clinical Pharmacology in Drug Development
- Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis
- (2018) B. Hameed et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
- (2018) Kris V. Kowdley et al. HEPATOLOGY
- Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH
- (2018) Naga Chalasani et al. LIVER INTERNATIONAL
- Diagnosis and Management of Primary Biliary Cholangitis
- (2018) Zobair M. Younossi et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis
- (2017) Sumeyye Samur et al. HEPATOLOGY
- Primary sclerosing cholangitis – a comprehensive review
- (2017) Tom H. Karlsen et al. JOURNAL OF HEPATOLOGY
- Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
- (2017) Valerio Nobili et al. LIVER INTERNATIONAL
- Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
- (2016) R. Pencek et al. DIABETES OBESITY & METABOLISM
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid
- (2014) J. R. F. Walters et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study
- (2014) Willem J. Lammers et al. GASTROENTEROLOGY
- Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma
- (2013) Jiyeon Hyeon et al. DIGESTIVE DISEASES AND SCIENCES
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
- (2012) Seiki Miura et al. BMC CANCER
- Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
- (2012) Luciano Adorini et al. DRUG DISCOVERY TODAY
- Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid
- (2012) Marco Carbone et al. GASTROENTEROLOGY
- Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis
- (2010) Teru Kumagi et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Nuclear Receptor Regulation of the Adaptive Response of Bile Acid Transporters in Cholestasis
- (2010) Martin Wagner et al. SEMINARS IN LIVER DISEASE
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- Primary Biliary Cirrhosis Associated withHLA, IL12A,andIL12RB2Variants
- (2009) Gideon M. Hirschfield et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started